Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

Weighted Avg Shares · Q4 FY2026 · quarter ended Sep 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q4 FY2026 weighted avg shares of 141.63M shares rose 4.4% year over year, behind the +6.5% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +4.4% toward the trailing-twelve-month pace of +6.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
141.63M-1.2% QoQ
Last fiscal yearSep 2026
141.63M+5.9% YoY
LTMSep 2026
141.87M+6.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.4%——
1 year+5.9%——
3-year CAGR+9.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2026
141.63M USD
Year-over-year change
+5.9%
4-year CAGR
+7.7%

Weighted Avg Shares vs competitors

How ARWR compares with its peers on the latest reported figures

  • ARWR's LTM Sep 2026 weighted avg shares of 141.87M shares is the 3rd highest of the 7 companies compared; the peer median is 118.61M shares.
  • Its year-over-year change of +6.5% is the 3rd highest of 6, against a peer median of +3.4%.
  • Over three fiscal years its annual growth of +9.9% compares with a peer median of +8.9%.
ARWR Competitors Peer median
Weighted Avg Shares for ARWR and competitors
Company Period LTM YoY 3-year CAGR
WVEWave Life Sciences Ltd.LTM Mar 2026178.01M +21.7%+28.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M +3.4%+4.1%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026141.87M +6.5%+9.9%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026132.45M +2.6%+2.5%
PRQRProQR Therapeutics N.V.LTM Mar 2026104.77M +19.6%+13.7%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+1.2%
Peer median (excluding ARWR) 118.61M+3.4%+8.9%

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue243.23M240.74M3.55M829.45M450.82M
Cost of Revenue10.42M12.49M18.6M01.8M
Gross Profit232.81M228.24M(15.04M)829.45M449.02M
Gross Margin95.7%94.8%-423.7%100.0%99.6%
Research & Development288.5M342.31M489.22M607.16M739.14M
Selling, General & Admin124.43M90.93M96.82M121.92M202.05M
Operating Expenses411.32M433.24M586.04M731.1M1.16B
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
EBITDA(162.29M)(175.67M)(561.51M)164.82M(603.59M)
EBITDA Margin-66.7%-73.0%-15812.8%19.9%-133.9%
Operating Income(178.51M)(205M)(601.08M)98.35M(707.17M)
Operating Margin-73.4%-85.2%-16927.1%11.9%-156.9%
Interest Income5.03M15.3M22.72M37.29M57.86M
Interest Expense018.33M32.35M89.36M93.71M
Other Income / Expenses5.8M(1.49M)(11.38M)(46.81M)(16.74M)
Income Before Tax(172.71M)(206.49M)(612.46M)51.53M(723.92M)
Pre-Tax Margin-71.0%-85.8%-17247.5%6.2%-160.6%
Income Tax Expense3.79M2.78M(2.77M)21.42M(6.78M)
Net Income(176.06M)(205.28M)(599.49M)(1.63M)(724.21M)
Net Margin-72.4%-85.3%-16882.4%-0.2%-160.6%
EPS (Basic)(1.67)(1.92)(5.00)(0.01)(5.11)
EPS (Diluted)(1.67)(1.92)(5.00)(0.01)(5.11)
Weighted Avg Shares105.43M106.75M119.78M133.76M141.63M
Weighted Avg Shares (Diluted)105.43M106.75M119.78M133.76M141.63M

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.